Every Form 4 that PAVmed Inc. (PAVM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PAVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAVM filings page.
Lee Victoria Tou-ho reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. reported that Chief Medical Officer Lee Victoria Tou-ho received a grant of 70,000 shares of common stock as an equity award. The restricted stock was granted at $0.00 per share and increases her direct holdings to 71,666 shares.
The award consists of restricted stock under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed, tying the grant to long-term employment and performance.
Aklog Lishan reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. Chairman and CEO Lishan Aklog received a grant of 350,000 shares of restricted common stock, awarded at $0.00 per share as equity compensation. The restricted stock was granted under PAVmed's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The award is subject to forfeiture if the required service period is not completed, tying the grant to long-term leadership retention. Following this grant, Dr. Aklog directly holds 357,614 shares of common stock, with additional indirect interests reported through family members and investment entities.
MCGRATH DENNIS M reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. reported that President and CFO Dennis M. McGrath received a grant of 180,000 shares of restricted common stock on April 2, 2026. The award was made under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
The restricted stock carries a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, McGrath directly holds 186,695 shares of PAVmed common stock.
Glennon Michael J reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Michael J. Glennon reported an award of 13,930 shares of restricted common stock as equity compensation. The shares were granted at no cash cost to him under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and have a single vesting date of May 20, 2029. The restricted stock is subject to forfeiture if he does not complete the required service period. Following this grant, Glennon directly holds 21,653 shares of PAVmed common stock.
Baxter Timothy E reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Timothy E. Baxter received a grant of 13,930 shares of restricted common stock as equity compensation. These shares vest on May 20, 2029 and may be forfeited if he does not complete the required service period. Following this award, he directly holds 21,097 common shares.
White Debra reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Debra White received a grant of 13,930 shares of restricted common stock as compensation. The award was granted at $0.00 per share under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed. Following this grant, White directly holds 21,097 shares of PAVmed common stock.
Sparks Ronald M reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Ronald M. Sparks received a grant of 13,930 shares of common stock as restricted stock under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. The award has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Sparks directly holds 21,097 shares of PAVmed common stock.
Agrawal Sundeep reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Sundeep Agrawal received a grant of 13,930 shares of restricted Common Stock as equity compensation. The award was granted at no cash purchase price and increases his direct holdings to 19,337 shares after the transaction.
The restricted stock was issued under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if he does not complete the required service period, tying the award to long-term board service.
Gordon Michael Adam reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. granted its General Counsel, Michael Adam Gordon, 110,000 shares of restricted common stock as equity compensation. The shares were granted at no cash cost and bring his direct holdings to 115,000 shares. The award vests on May 20, 2029 and is subject to forfeiture if he does not complete the required service period, making this a long-term retention incentive rather than an open-market purchase.
O'Neil Shaun reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. Chief Operating Officer Shaun O'Neil received a grant of 110,000 shares of common stock as restricted stock under the company's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. The award has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, O'Neil directly holds 115,598 shares of PAVmed common stock.
PAVmed Inc. director Ronald M. Sparks reported a grant of 150,000 restricted shares on 09/30/2025. The shares were issued at a price of $0 and carry a single vesting date of May 20, 2028. After the grant, the reporting person beneficially owns 215,000 shares in total. The restricted stock is subject to forfeiture if the required service period is not completed.
Debra White, a director of PAVmed Inc. (PAVM), was granted 150,000 shares of restricted common stock on 09/30/2025. The shares were issued at a price of $0 and, after the grant, Ms. White beneficially owns 215,000 shares. The restricted stock vests on May 20, 2028 and is subject to forfeiture if the required service period is not completed.
Timothy E. Baxter, a director of PAVmed Inc. (PAVM), received a grant of 150,000 restricted shares of common stock on 09/30/2025. After the grant, Mr. Baxter beneficially owned 215,000 shares in total. The restricted shares vest on a single date, May 20, 2028, and are subject to forfeiture if the required service period is not completed. The award was made under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and was reported on a Form 4.
Michael J. Glennon, a director of PAVmed Inc. (PAVM), was granted 150,000 restricted shares on 09/30/2025 under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan at a reported price of $0. After the grant his total beneficial ownership is reported as 231,667 shares. The restricted shares vest on May 20, 2028 and are subject to forfeiture if the required service period is not completed. The Form 4 was signed by power of attorney on 10/02/2025.
Sundeep Agrawal, a director of PAVmed Inc. (PAVM), reported an acquisition of 150,000 shares of common stock on 09/30/2025 via restricted stock granted under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The shares carry a single vesting date of May 20, 2028 and are subject to forfeiture if the required service period is not completed. Following the grant, the reporting person’s beneficial ownership is reported as 162,195 shares. The Form 4 was signed by power of attorney on 10/02/2025.
PAVmed Inc. (PAVM) reported a Form 4 showing that Michael A. Gordon, the company's General Counsel, was granted 150,000 shares of common stock on 09/30/2025. The award is restricted stock issued under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carries a single vesting date of May 20, 2028. The shares have a reported acquisition price of $0 and are subject to forfeiture if the required service period is not completed. Following the grant, the reporting person beneficially owns 150,000 shares directly. The form is signed by the reporting person on 10/02/2025.
PAVmed Inc. (PAVM) reporting person Dennis M. McGrath, who is identified as President and CFO, received a grant of 150,000 shares of restricted common stock on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carry a single vesting date of May 20, 2028; they are subject to forfeiture if the required service period is not completed. The Form 4 shows 200,834 shares beneficially owned by the reporting person after the transaction. The reported transaction lists a price of $0, indicating these were restricted shares rather than a cash purchase. The filing was executed by power of attorney and dated 10/02/2025.
Dr. Lishan Aklog, Chairman and CEO of PAVmed Inc. (PAVM), reported on Form 4 the grant of 150,000 restricted shares on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan at a $0 purchase price and vest on May 20, 2028, subject to forfeiture if service requirements are not met. After the transaction Dr. Aklog directly beneficially owns 228,418 shares and indirectly holds additional positions: 154 shares via his daughter, 152 via his son, 297,105 through Pavilion Venture Partners LLC (of which he is sole manager), and 1,333 through HCFP/AG LLC (co-managed). The filing was signed by power of attorney on 10/02/2025.
Shaun O'Neil, Chief Operating Officer of PAVmed Inc. (PAVM), was granted 150,000 shares of restricted common stock on 09/30/2025 under the company’s Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The restricted shares carry a $0 purchase price and vest on May 20, 2028, and are subject to forfeiture if the required service period is not completed. After the grant, the reporting person beneficially owned 167,933 shares. The filing was reported on Form 4 and signed by power of attorney on 10/02/2025.